 Cyclerion Therapeutics, Inc. CYCN, a clinical-stage biopharmaceutical company developing soluble guanylate cyclase sGC stimulators for the treatment of serious and orphan diseases, today announced upcoming medical meeting presentations highlighting its commitment to sickle cell disease patients and supporting its therapeutic approach to treating the disease through sGC stimulation. Cyclerion will present at the Annual National Convention of the Sickle Cell Disease Association of America SCDAA, held October 9-12 in Baltimore, and at the Annual Sickle Cell Disease and Thalassaemia Conference ASCAT, held October 21-23 in London. Cyclerion and its collaborators will present new research from a sickle cell disease patient journey project. 